SCHEMBL4352280

SCHEMBL4352280

CCC(C)Nc1cc(C)cc(COc2c(Br)cc(C(=O)NCC(=O)O)cc2Br)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MCL1 Q07820 1/20 0.39
THRB P10828 8/20 0.39
THRA P10827 7/20 0.39
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
PAX8 Q06710 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
PDE5A O76074 1/20 0.36
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DHODH Q02127 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351934 0.92 THRA (0.42) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4932888 0.90 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4931943 0.90 HPGD (0.39) SMN1; SMN2MEN1KMT2ARAB9ANPC1
SCHEMBL4932371 0.89 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4360612 0.87 THRA (0.51) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL5717937 0.87 THRA (0.44) MEN1KMT2AMCL1THRBTHRA
SCHEMBL4923977 0.87 SMN1; SMN2 (0.37) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4931455 0.87 THRA (0.41) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL5718180 0.86 MEN1 (0.36) SMN1; SMN2MEN1KMT2ATHRBTHRA
SCHEMBL4354094 0.85 THRB (0.50) SMN1; SMN2MEN1KMT2ATHRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009080835-A1 THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING KARO BIO AB (SE) 2009-07-02 WO claimed
US-20080221210-A1 Thyroid Receptor Agonists KARO BIO AB (SE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221210-A1 Thyroid Receptor Agonists TSHR, TRHR, THRA SMN1; SMN2 4282/4885MEN1 773/4885KMT2A 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.